TaiMed Biologics (ROCO:4147) Other Financing: NT$-0.9 Mil (TTM As of Dec. 2025)


ROCO:4147 TaiMed Biologics Inc ROCO:4147
55 GF Score
Price NT$69.50
GF Value NT$85.93
Valuation Modestly Undervalued
View Full Analysis

What is TaiMed Biologics Other Financing?

TaiMed Biologics ROCO:4147 55 Other Financing is NT$-0.9 Mil as of Dec. 2025. GuruFocus rates ROCO:4147 with a GF Score™ of 55/100 and a GF Value™ of NT$85.93 (Modestly Undervalued).

TaiMed Biologics's Other Financing for the three months ended in Dec. 2025 was NT$0.0 Mil.

TaiMed Biologics's Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 was NT$-0.9 Mil.

TaiMed Biologics Other Financing Historical Data

* Premium members only.

The historical data trend for TaiMed Biologics's Other Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TaiMed Biologics Other Financing Chart

TaiMed Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 0.05 0.00 -4.27 -0.92

TaiMed Biologics Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Other Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.92 0.00
ROCO:4147
55GF Score
TaiMed Biologics Inc ROCO:4147
Other Financing is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TaiMed Biologics Other Financing Calculation

Other Financing represents other cash flow from financing activity that not otherwise classified, which includes:
Proceeds From Stock Option Exercised
Other Financing Charges

Other Financing for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-0.9 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Other Financing →
What does a Other Financing of NT$-0.9 Mil mean?
TaiMed Biologics (ROCO:4147) has a Other Financing of NT$-0.9 Mil as of Dec. 2025. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for TaiMed Biologics and its competitors.
Is TaiMed Biologics' Other Financing too high?
TaiMed Biologics' current Other Financing is NT$-0.9 Mil. Overall, TaiMed Biologics has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does TaiMed Biologics' Other Financing compare to VRTX and REGN?
TaiMed Biologics' Other Financing of NT$-0.9 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Financing for a Biotechnology company?
A good Other Financing depends on the Biotechnology industry context. However, Other Financing should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Financing mean?
A high Other Financing can signal that a stock is expensive relative to its fundamentals. Other Financing represents other cash flow from financing activity that not otherwise classified. View historical data for TaiMed Biologics and its competitors. TaiMed Biologics's current Other Financing is NT$-0.9 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TaiMed Biologics stock overvalued right now?
Based on GuruFocus' analysis, TaiMed Biologics (ROCO:4147) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$85.93, compared to a current price of NT$69.50 — trading 19.1% below its estimated fair value. The current Other Financing is NT$-0.9 Mil. TaiMed Biologics' overall GF Score™ is 55/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Financing calculated?
Other Financing is calculated from a company's financial statements. For TaiMed Biologics (ROCO:4147), the current Other Financing is NT$-0.9 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is TaiMed Biologics (ROCO:4147) Overvalued in 2026?

Based on GuruFocus' analysis, TaiMed Biologics stock appears to be undervalued. The current stock price of NT$69.50 is trading 19.1% below its estimated GF Value™ of NT$85.93. GuruFocus considers TaiMed Biologics to be Modestly Undervalued.

Key valuation signals for ROCO:4147:

  • Other Financing: NT$-0.9 Mil
  • GF Value™: NT$85.93 vs. price of NT$69.50 (19.1% below fair value)
  • GF Score™: 55/100

No single metric tells the full story. See the ROCO:4147 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

TaiMed Biologics Business Description

Address No. 607, Ruiguang Road, 3rd Floor, Neihu District, Taipei, TWN, 11492
TaiMed Biologics Inc is a biotechnology company engaged in developing, manufacturing, and commercializing new drugs for the treatment and prevention of infectious diseases. Its products include Trogarzo IV Infusion, Trogarzo IV Push, TMB-365, TMB-365/TMB-380 combination, and Antibody-Drug Conjugates (ADCs). The Group operates in the Americas, which generates maximum revenue, as well as Europe and Taiwan.
55GF Score

Get the complete analysis for ROCO:4147

Other Financing is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$69.50
Price
NT$85.93
GF Value